AIM (AIM ImmunoTech) Insider Ownership: 23.11 % (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AIM AIM ImmunoTech Inc AIM
22 GF Score
Price $0.25
GF Value $0.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Insider Ownership?

AIM ImmunoTech AIM +6.26% 22 Insider Ownership is 23.11 % as of Aug. 21, 2026. GuruFocus rates AIM with a GF Score™ of 22/100 and a GF Value™ of $0.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AIM ImmunoTech's insider ownership is 23.11%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AIM ImmunoTech's Institutional Ownership is 0.63%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AIM ImmunoTech's Float Percentage Of Total Shares Outstanding is 99.54%.

AIM ImmunoTech Insider Ownership Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Insider Ownership Chart

AIM ImmunoTech Historical Data

The historical data trend for AIM ImmunoTech can be seen below:

2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 8.19 8.48 8.13 8.20 8.83 14.17 13.41 78.63 23.11 23.11
AIM
22GF Score
AIM ImmunoTech Inc AIM
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 23.11 % mean?
AIM ImmunoTech (AIM) has a Insider Ownership of 23.11 % as of Aug. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Insider Ownership too high?
AIM ImmunoTech's current Insider Ownership is 23.11 %. Overall, AIM ImmunoTech has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Insider Ownership compare to NIKI and PMCB?
AIM ImmunoTech's Insider Ownership of 23.11 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Insider Ownership is 23.11 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.90, compared to a current price of $0.25 — trading 71.9% below its estimated fair value. The current Insider Ownership is 23.11 %. AIM ImmunoTech's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Insider Ownership is 23.11 % as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.25 is trading 71.9% below its estimated GF Value™ of $0.90. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Insider Ownership: 23.11 %
  • GF Value™: $0.90 vs. price of $0.25 (71.9% below fair value)
  • GF Score™: 22/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
22GF Score

Get the complete analysis for AIM

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.90
GF Value